Prostate cancer is the most commonly diagnosed cancer in the UK. But screening is not universal, and charities are divided over whether it should be extended. What do those living with the disease ...

Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding ...

Nearly 300 abstracts on prostate cancer research from around the world will be presented at the European Association of Urology Congress (EAU26 ...

Esaote Group, a leading Italian innovator in medical imaging - ultrasound, dedicated magnetic resonance and medical IT, is ...

The biopsy came back positive. It’s lung cancer.” Countless people in our community hear these words no one ever expects.

Profound Medical (PROF) announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic ...

Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, ...

Market has emerged as a rapidly expanding segment within the oncology diagnostics and liquid biopsy landscape. Circulating Tumor Cells are cancerous cells that detach from primary or metastatic tumors ...

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA treatment ...

The Company's Appearance on the Prestigious List Denotes Its Innovative Approach and Role in Moving Multi-Cancer Early Detection Screening Forward ...

Esaote presents its new and innovative technology dedicated to urology: the exclusive Prostate Attention Map (PAM), now ...